reference/2655109

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/2655109

Outgoing Links

Predicate	Object
contentType	Journal Article
endingPage	2400
issn	0017-5749 1468-3288
issueIdentifier	12
pageRange	2398-2400
publicationName	Gut
startingPage	2398
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_fe78b2dc4d28529ed9007d101fc7c80a
bibliographicCitation	McGregor CG, Adams A, Sadler R, Arancibia-Cárcamo CV, Palmer R, Ambrose T, Brain O, Walsh A, Klenerman P, Travis SP, Croft NM, Lindsay JO, Satsangi J. Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic. Gut. 2021 Dec;70(12):2398–400. doi: 10.1136/gutjnl-2021-324116. PMID: 33579788.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2213a44d197b657cdc8a7f6c66f03494 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4090-0375 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-9364-8540 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-1519-6435 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ebddb6ece9f62676c8df6a2e74ee98a8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_040877a119257c54512d7504a80e73f0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d43ceaaf1a7754bc6a573df4fe1054aa http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_65fd8e9f36267e2e23de0c2f0f36366c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_198454ea87fd91f04d25bed552b0d99c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_eaa99778ea647f7eac2fa57b94b18175 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_906a68502c7480a7da4fbd5babe52cd7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f9f897adb441ec63400aa385032bc482 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-2690-4361
date	2021-02-12^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1136/gutjnl-2021-324116 https://pubmed.ncbi.nlm.nih.gov/33579788
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3923 https://portal.issn.org/resource/ISSN/0017-5749 https://portal.issn.org/resource/ISSN/1468-3288
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic
discusses	http://id.nlm.nih.gov/mesh/M0282056 http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0539116
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000086382 http://id.nlm.nih.gov/mesh/D015212Q000188 http://id.nlm.nih.gov/mesh/D015212Q000453
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D006113Q000453 http://id.nlm.nih.gov/mesh/D000086402 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D061067 http://id.nlm.nih.gov/mesh/D000069285 http://id.nlm.nih.gov/mesh/D058873
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10792 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6762

Showing number of triples: 1 to 47 of 47.